Intracellular pharmacokinetics of anthracyclines in human leukemia cells: Correlation of DNA-binding with apoptotic cell death

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 1, 1998, Pages 25-28

  Gieseler, F ^a,c   Nussler V ^b   Brieden, T ^a   Kunze, J ^a   Valsamas, S ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Medizinische Poliklinik   (Germany)

Author keywords

Anthracyclines; Cellular resistance; DNA binding

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; IDARUBICIN;

APOPTOSIS; BONE MARROW CELL; CELL DEATH; CELL VACUOLE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPOPHILICITY; MEMBRANE TRANSPORT;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL NUCLEUS; DAUNORUBICIN; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; IDARUBICIN; LEUKEMIA;

EID: 2642643778     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Binaschi M, Zunino F, Capranico G 1995 Mechanism of action of DNA topoisomerase inhibitors. Stem Cells (Dayt) 13: 369-379
2. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M, Strolin BM, Efthymiopoulos C, Pannuti F 1992 Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 30: 307-316
3. Corbett AH, Hong D, Osheroff N 1993 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem 268: 14394-14398
4. D'Incalci M 1993 DNA-topoisomerase inhibitors. Curr Opin Oncol 5: 1023-1028
5. Dietel M, Arps H, Lage H, Niendorf A 1990 Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50: 6100-6106
6. Gieseler F, Biersack H, Brieden T, Manderscheid J, Nussler V 1994 Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol 69: 13-17
7. Gieseler F, Boege F, Clark M, Meyer P 1993 Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation. Toxicol Lett 67: 331-340
8. Gieseler F, Glasmacher A, Kampfe D, Wandt H, Nuessler V, Valsamas S, Kunze J, Wilms K 1996 Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia 10: 1177-1180
9. Hollingshead LM, Faulds D 1991 Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42: 690-719
10. Ling V 1992 P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2609
11. Lowe SW, Ruley HE, Jacks T, Houseman DE 1993 p53-dependent apoptosis modulates the cytotoxcity of anticancer agents. Cell 74: 957-967
12. Lown JW 1993 Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol Ther 60: 185-214
13. McKelvey-Martin V, Green MH, Schmezer P, Pool ZB, De MM, Collins A 1993 The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res 288: 47-63
14. Negri C, Bernardi R, Donzelli M, Scovassi AI 1995 Induction of apoptotic cell death by DNA topoisomerase II inhibitors. Biochimie 77: 893-899
15. Nussler V, Pelka Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W 1996 P-glycoprotein expression in patients with acute leukemia - clinical relevance. Leukemia 10: 23-31
16. Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gullis E, Gieseler F, Bock S, Bartl R, Petrides PE et al 1994 Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - first experience with their reversal. Ann Hematol 69: 25-29
17. Page B, Page M, Noel C 1993 A new flourimetric assay for cytotoxicity measurements in vitro. Int J Oncol 3: 473-476
18. Pullman B 1991 Sequence specificity in the binding of anti-tumour anthracyclines to DNA: a success of theory. Anticancer Drug Des 6: 95-105
19. Robert J, Gianni L 1993 Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17: 219-252
20. Robinson MJ, Corbett AH, Osheroff N 1993 Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 32: 3638-3643
21. Sachs L, Lotem J 1993 Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15-21
22. Solary E, Bertrand R, Pommier Y 1994 Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma 15: 21-32
23. Zunino F, Capranico G 1990 DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-Cancer Drug Design 5: 307-317